What We're Reading: Page
Industry reads hand-picked by our editors
Oct 30, 2024
-
Reuters
Gradual dosing of Lilly Alzheimer’s drug cuts brain-swelling risk, study finds
-
Fierce Pharma
Novartis’ Scemblix leaps into newly diagnosed leukemia—where winning over doctors may take time
-
CNN
What alarms health experts most about RFK Jr. is what he’s leaving out of his health policy proposals
Oct 29, 2024
Oct 28, 2024
-
The Financial Times
Jeff Smith, the activist picking a fight with Covid hero Pfizer
-
LifeSciVC
Biotech Risk Cycles: Assets And Platforms
-
Boston Business Journal
BiotechTV’s new MassBio studio helps bring Kendall Square to the world
Oct 25, 2024
Oct 24, 2024
Oct 23, 2024
-
The New York Times
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
-
Stat News
Novo asks FDA to bar compounders from making semaglutide copies
-
The Wall Street Journal
Cancer Care Is Getting Personal. Local Doctors Can’t Keep Up.
-
The Guardian
Alzheimer’s drug rejected for widespread NHS use in England
Oct 22, 2024
-
The Wall Street Journal
J&J’s Ketamine-Derived Drug Is Taking Off
-
The New York Times
First Sickle Cell Gene Therapy Patient, 12, Leaves Hospital
-
FirstWord Pharma
HIV weekly combo from Gilead, Merck & Co. achieves long-term viral suppression
Previous
